Abstract
HIV is the most significant risk factor for many opportunistic infections like fungal, tuberculosis, etc. The intense media coverage of AIDS puts the public on an emotional roller caster, and inflated promises are engendered by each success. For the moment drugs acting as both HIV-reverse transcriptase inhibitors along with antimicrobial properties are one of the brightest hope. The Non-nucleoside reverse transcriptase inhibitors (NNRTIs) appear ideally suited for further development in the chemoprophylaxis and therapy of HIV infections. In recent years, isatinimino compounds have been reported to exhibit broad-spectrum chemotherapeutic properties that include anti-HIV, antituberculous, antifungal and antibacterial activities. Hence these leads should be regarded as structural hits in the search for more potent antimicrobial compounds with broad-spectrum chemotherapeutic properties for the effective treatment of HIV / AIDS. This review focuses on the design of isatinimino compounds, which resemble the NNRTIs for the development of an ideal anti-HIV drug.
Keywords: broad spectrum chemotherapeutic, hiv, aids, opportunistic infections, hiv-reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors
Current Medicinal Chemistry
Title: Towards the Design and Development of Agents with Broad Spectrum Chemotherapeutic Properties for the Effective Treatment of HIV / AIDS
Volume: 10 Issue: 17
Author(s): Dharmarajan Sriram and Perumal Yogeeswari
Affiliation:
Keywords: broad spectrum chemotherapeutic, hiv, aids, opportunistic infections, hiv-reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors
Abstract: HIV is the most significant risk factor for many opportunistic infections like fungal, tuberculosis, etc. The intense media coverage of AIDS puts the public on an emotional roller caster, and inflated promises are engendered by each success. For the moment drugs acting as both HIV-reverse transcriptase inhibitors along with antimicrobial properties are one of the brightest hope. The Non-nucleoside reverse transcriptase inhibitors (NNRTIs) appear ideally suited for further development in the chemoprophylaxis and therapy of HIV infections. In recent years, isatinimino compounds have been reported to exhibit broad-spectrum chemotherapeutic properties that include anti-HIV, antituberculous, antifungal and antibacterial activities. Hence these leads should be regarded as structural hits in the search for more potent antimicrobial compounds with broad-spectrum chemotherapeutic properties for the effective treatment of HIV / AIDS. This review focuses on the design of isatinimino compounds, which resemble the NNRTIs for the development of an ideal anti-HIV drug.
Export Options
About this article
Cite this article as:
Sriram Dharmarajan and Yogeeswari Perumal, Towards the Design and Development of Agents with Broad Spectrum Chemotherapeutic Properties for the Effective Treatment of HIV / AIDS, Current Medicinal Chemistry 2003; 10 (17) . https://dx.doi.org/10.2174/0929867033457142
DOI https://dx.doi.org/10.2174/0929867033457142 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Therapeutic Use of Chemokines
Current Pharmaceutical Design Editorial (Mucosal Co-Infections and HIV-1 Transmission and Pathogenesis)
Current HIV Research New Antimicrobial Approaches: Reuse of Old Drugs
Current Drug Targets Immunomodulatory Properties of Antibiotics
Current Molecular Pharmacology The Effects of Melatonin on the Oxidative Stress and Duration of Atrial Fibrillation after Coronary Artery Bypass Graft Surgery: A Randomized Controlled Trial
Endocrine, Metabolic & Immune Disorders - Drug Targets Label-Free Mass Spectrometry-Based Plasma Proteomics Identified LY6D, DSC3, CDSN, SERPINB12, and SLURP1 as Novel Protein Biomarkers For Pulmonary Tuberculosis
Current Proteomics Graphical Abstracts
Letters in Drug Design & Discovery Sterol 14α-Demethylase from Trypanosomatidae Parasites as a Promising Target for Designing New Antiparasitic Agents
Current Topics in Medicinal Chemistry Withdrawal Notice: A Panoramic View on the Phytochemical, Nutritional and Therapeutic value of Ziziphus mauritiana Lam.: A Comprehensive Review
Mini-Reviews in Medicinal Chemistry The Gut Microbiota in Inflammatory Bowel Disease
Current Pharmaceutical Design Novel Approaches to Control Biofilm Infections
Current Medicinal Chemistry Role of Estradiol in the Expression of Genes Involved in Serotonin Neurotransmission: Implications for Female Depression
Current Neuropharmacology Recent Advances in Metabolomics
Current Metabolomics Are Viruses and Parasites Linked to Celiac Disease? A Question that Still has no Definite Answer
Current Pharmaceutical Biotechnology Microfluidics as an Emerging Platform for Tackling Antimicrobial Resistance (AMR): A Review
Current Analytical Chemistry Synthesis and Evaluation of Tetrazole-BasedHydrazone Derivatives Bearing a Pyridine Moiety as Antimicrobial Agents
Letters in Drug Design & Discovery Foreword
Current Topics in Medicinal Chemistry Crosstalk between Behavior and Immune System During the Prodromal Stages of Alzheimer`s Disease
Current Pharmaceutical Design The CD4C/HIVNef Transgenic Model of AIDS
Current HIV Research Theoretical Modeling of HPV: QSAR and Novodesign with Fragment Approach
Current Computer-Aided Drug Design